𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

✍ Scribed by Catherine Thieblemont; Daciana Antal; Laurence Lacotte-Thierry; Vincent Delwail; Daniel Espinouse; Anne-Sophie Michallet; Catherine Traulle; Fadhela Bouafia-Sauvy; Christine Giraud; Gilles Salles; François Guilhot; Bertrand Coiffier

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
122 KB
Volume
104
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

The authors evaluated the efficacy of chemotherapy combined with rituximab followed by high‐dose therapy (HDT) plus autologous stem cell transplantation in patients with mantle cell lymphoma (MCL).

METHODS

This was a retrospective analysis of 34 patients who were treated in 2 departments of hematology, including 29 patients (85%) who received first‐line treatment. Rituximab was administered as 4 injections just before harvest in 25 patients (73%) or simultaneously with chemotherapy in 9 patients (27%). HDT included total body irradiation in 26 patients (77%).

RESULTS

After induction therapy, all patients except one reached a response: There were 14 (41%) complete responses (CR) and 19 (56%) partial responses (PR). Stem cell harvest was successful in all patients but 2, with a median number of 5.9 CD34‐positive cells per 10^6^/kg. Three months after transplantation, 24 patients (71%) were in CR, and 7 patients (21%) were in PR. At 3 years from the day of transplantation, the estimated overall survival was 87%. With a median follow‐up at 2.6 years, the estimated median time to disease progression was 3.4 years. Rituximab treatment before harvest did not delay hematopoietic reconstitution: The median time it took patients to recover absolute neutrophil count to > 0.5 G/L was 10 days.

CONCLUSIONS

Chemotherapy combined with rituximab followed by HDT improved the overall survival and progression‐free survival in patients MCL without adding toxicities. Cancer 2005. © 2005 American Cancer Society.

📜 SIMILAR VOLUMES

High dose radiochemotherapy followed by
High dose radiochemotherapy followed by autologous stem cell transplantation in four patients with multiple lymphomatous polyposis
✍ Béatrice Mahé; Anne Moreau; Philippe Moreau; Stéphane Le Tortorec; Jean-Luc Haro 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB 👁 2 views

## Background: Multiple lymphomatous polyposis (mlp) results from gastrointestinal involvement by a b-cell lymphoma that originates from the mantle zone of lymphoid follicles. this well described clinicopathologic entity has a poor prognosis: the rate of complete response after conventional chemoth

Safety and efficacy of high-dose chemoth
Safety and efficacy of high-dose chemotherapy with autologous stem cell transplantation for patients with malignant astrocytomas
✍ Benjamin Chen; Tauseef Ahmed; Anney Mannancheril; Michael Gruber; Deborah L. Ben 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND Malignant astrocytomas are among the most resistant tumors to curative treatments. Mean survival without treatment is measured in weeks, and even with maximal surgery and radiation, the mean reported survival is < 1 year. The advent of supportive treatments and newer agen

Primary AL amyloid polyneuropathy succes
Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation
✍ Nagaaki Katoh; Masayuki Matsuda; Takuhiro Yoshida; Masahide Yazaki; Hiroshi Mori 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

## Abstract We report 2 patients with polyneuropathy associated with amyloid derived from light chains (AL) who were treated successfully with high‐dose melphalan followed by autologous peripheral blood stem cell transplantation (HDM/SCT). Neuropathic symptoms improved in conjunction with normaliza

High-dose intravenous methotrexate follo
High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis
✍ Irene M. Ghobrial; Francis Buadi; Robert J. Spinner; Joseph P. Colgan; Alexandra 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

## Abstract ## BACKGROUND Neurolymphomatosis (NL) is a rare neurologic manifestation of systemic lymphoma characterized by lymphomatous infiltration of the peripheral nervous system. The diagnosis of NL is difficult and requires a multidisciplinary approach for obtaining an adequate biopsy specime